PhaseRx, Inc. Stock

PZRXQ

US71723F1030

Biotechnology & Medical Research

Delayed OTC Markets 21:06:20 26/08/2026 +04			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-

31/01/19	Roivant Sciences GmbH cancelled the acquisition of substantially all of the assets from PhaseRx, Inc.	CI
23/03/18	PhaseRx, Inc. Bankruptcy Case Dismissed	CI

Pz Wind Down, Inc., formerly, PhaseRx, Inc. is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The Company's i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
PZRXQ Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	4.56M 4.01M 3.8M 3.43M 6.47M 437M 6.56M 45.51M 17.51M 223M 17.12M 16.75M 716M	P/E 2015 *	-	P/E 2016	-0.58x
Enterprise Value	-5.22M -4.59M -4.35M -3.93M -7.41M -500M -7.5M -52.08M -20.04M -256M -19.59M -19.16M -820M	EV / Sales 2015 *	-	EV / Sales 2016	-
Free-Float	100%	Yield 2015 *	-	Yield 2016	-

31/01/19	Roivant Sciences GmbH cancelled the acquisition of substantially all of the assets from PhaseRx, Inc.	CI
23/03/18	PhaseRx, Inc. Bankruptcy Case Dismissed	CI
07/03/18	Motion for Case Dismissal Filed for PhaseRx, Inc.	CI
20/02/18	Motion for De Minimis Asset Sale Approved for PhaseRx, Inc.	CI
02/02/18	PhaseRx, Inc.(OTCPK:PZRX.Q) dropped from NASDAQ Composite Index	CI
01/02/18	Motion for Asset Sale Approved for PhaseRx, Inc.	CI
01/02/18	Roivant Sciences GmbH entered into an asset purchase agreement to acquire substantially all of the assets from PhaseRx, Inc. for $6.8 million.	CI
27/12/17	Bidding Procedure Approved for PhaseRx, Inc.	CI
14/12/17	PhaseRx Considers Multiple Alternatives	CI
13/12/17	PhaseRx, Inc.(NasdaqCM:PZRX) dropped from S&P TMI Index	CI
11/12/17	PhaseRx, Inc. Filed for Bankruptcy	CI
11/12/17	Motion for Asset Sale Filed by PhaseRx, Inc.	CI
09/11/17	PhaseRx, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	CI

Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0.02
10 years	0		3.3

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PHASERX, INC.	-.--%	-.--%	-	-	11
WUXI APPTEC CO., LTD.	+4.16%	-0.36%	+49.37%	+94.17%	74.46B
ARGENX SE	-0.64%	+0.65%	+27.03%	+79.91%	60.14B
LONZA GROUP AG	-2.33%	-1.23%	+5.31%	+33.89%	48.15B
IQVIA HOLDINGS INC.	-1.48%	-3.28%	+30.53%	+37.20%	44.25B
REVOLUTION MEDICINES, INC.	+2.35%	+4.92%	+357.24%	+701.26%	43.99B
BEONE MEDICINES AG	-0.64%	+1.64%	+9.17%	+104.97%	41.61B
CELLTRION, INC.	-0.67%	+0.17%	+7.60%	+46.37%	29.97B
WUXI BIOLOGICS (CAYMAN) INC.	+4.77%	+6.16%	+36.77%	+22.78%	29.31B
INSMED INCORPORATED	-2.54%	-7.30%	-23.50%	+344.13%	24.93B
Average	+0.28%	+1.38%	+55.50%	+162.74%	39.68B
Weighted average by Cap.	+0.55%	+1.53%	+59.79%	+153.60%

	2015	2016
Net sales	375K 330K 313K 282K 532K 35.96M 539K 3.74M 1.44M 18.38M 1.41M 1.38M 58.93M	-
Net income	-7.38M -6.5M -6.15M -5.56M -10.47M -707M -10.61M -73.64M -28.34M -362M -27.7M -27.1M -1.16B	-20.14M -17.73M -16.8M -15.17M -28.59M -1.93B -28.96M -201M -77.36M -987M -75.61M -73.97M -3.16B
Net Debt	16.55M 14.57M 13.81M 12.47M 23.5M 1.59B 23.8M 165M 63.58M 811M 62.15M 60.79M 2.6B	-9.78M -8.61M -8.16M -7.36M -13.88M -937M -14.06M -97.59M -37.55M -479M -36.71M -35.91M -1.54B

PhaseRx, Inc. Stock

Stocks

PZRXQ

US71723F1030

Biotechnology & Medical Research

Valuation: PhaseRx, Inc.

Chart: PhaseRx, Inc.

Latest news: PhaseRx, Inc.

Price Extremes

Bio Therapeutic Drugs

Financials

Company Profile